NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Pawar Law Group reminds shareholders who purchased shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) from February 22, 2017 through May 1, 2018, both dates inclusive (the "Class Period") of the important July 6, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Esperion investors under the federal securities laws. To join the Esperion class action, go to http://pawarlawgroup.com/cases/esperion-therapeutics-inc/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email email@example.com for information on the class action.
No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. You may also remain an absent class member and do nothing at this point. You may retain counsel of your choice.
According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Esperion's cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death; and (2) as a result, Esperion's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 6, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/esperion-therapeutics-inc/ to join the class action. You may also contact Vik Pawar of Pawar Law Group toll-free at 888-589-9804 or via email at firstname.lastname@example.org.
Pawar Law Group represents investors from around the world.
Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
SOURCE: Pawar Law Group